Cytek Biosciences, Inc.
CTKB
$4.14
-$0.03-0.72%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 63.53% | 2.23% | 50.44% | 28.98% | -183.89% |
| Total Depreciation and Amortization | 15.09% | 10.37% | 13.65% | 17.36% | 44.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -54.19% | -37.41% | -29.46% | 23.66% | 16.09% |
| Change in Net Operating Assets | -99.65% | 172.00% | 173.39% | 182.16% | 104.00% |
| Cash from Operations | -1.51% | 233.81% | 380.57% | 1,576.55% | 1,284.50% |
| Capital Expenditure | 2.67% | 19.17% | 24.16% | 57.32% | 52.95% |
| Sale of Property, Plant, and Equipment | 252.63% | -- | -- | -- | -- |
| Cash Acquisitions | -98.73% | -98.73% | 98.96% | 99.47% | 99.47% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -211.77% | -186.03% | -79.68% | 111.55% | 144.57% |
| Cash from Investing | -225.92% | -197.89% | 11.63% | 105.47% | 131.36% |
| Total Debt Issued | 249.75% | 149.43% | -- | -53.20% | -53.37% |
| Total Debt Repaid | -248.74% | -246.95% | 1.42% | -17.47% | -64.99% |
| Issuance of Common Stock | -47.54% | -37.89% | -18.18% | 1.07% | 18.91% |
| Repurchase of Common Stock | 25.41% | 26.62% | 50.27% | -409.22% | -3,491.71% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 29.09% | 27.91% | 62.16% | -991.63% | -1,098.01% |
| Foreign Exchange rate Adjustments | -134.16% | 20.07% | 413.63% | 234.91% | 255.15% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -320.92% | -300.95% | 47.76% | 99.25% | 121.24% |